Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.37 |
| ▸ | FLT1 | P17948 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 3/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22045820 | 0.91 | MAP2K1 (0.45) | MAP2K1FLT1MAP2K2HDAC3HDAC1 | |
| SCHEMBL24906176 | 0.89 | MAP2K1 (0.40) | CSF1RIKBKBMAP2K1FLT1KDR | |
| SCHEMBL24906390 | 0.88 | MAP2K1 (0.48) | MAP2K1KCNH2MAP2K2 | |
| SCHEMBL26047319 | 0.86 | MAP2K1 (0.43) | CSF1RMAP2K1MAP2K2 | |
| SCHEMBL22045823 | 0.85 | MAP2K1 (0.43) | CSF1RMAP2K1FLT1KDRKCNH2 | |
| SCHEMBL24088840 | 0.84 | MAP2K1 (0.51) | MAP2K1MAP2K2BRAF | |
| SCHEMBL26047314 | 0.84 | MAP2K1 (0.51) | MAP2K1MAP2K2BRAF | |
| SCHEMBL24906369 | 0.84 | MAP2K1 (0.51) | MAP2K1MAP2K2BRAF | |
| SCHEMBL24906181 | 0.84 | CSF1R (0.39) | CSF1RIKBKBMAP2K1FLT1KDR | |
| SCHEMBL24088798 | 0.81 | MAP2K1 (0.47) | MAP2K1KCNH2MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | CSF1R 2681/4885IKBKB 2658/4885MAP2K1 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.